Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX1 | P51575 | 4/20 | 0.44 |
| ▸ | P2RX3 | P56373 | 4/20 | 0.44 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.44 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.43 |
| ▸ | RNASEL | Q05823 | 2/20 | 0.42 |
| ▸ | P2RY1 | P47900 | 5/20 | 0.42 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.42 |
| ▸ | SRC | P12931 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | ENTPD1 | P49961 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31539951 | 0.80 | HIF1A (0.41) | SMN1; SMN2 | |
| SCHEMBL17453498 | 0.76 | P2RY2 (0.41) | P2RX1P2RX3P2RX2RNASELP2RY1 | |
| Rdv-Tp SCHEMBL10120881 | 0.75 | POLRMT (0.51) | P2RX1P2RX3P2RX2P2RX4RNASEL | |
| Rdv-Tp SCHEMBL26003192 | 0.75 | POLRMT (0.51) | P2RX1P2RX3P2RX2P2RX4RNASEL | |
| Rdv-Tp SCHEMBL23278555 | 0.75 | POLRMT (0.51) | P2RX1P2RX3P2RX2P2RX4RNASEL | |
| Rdv-Tp SCHEMBL24492745 | 0.75 | POLRMT (0.51) | P2RX1P2RX3P2RX2P2RX4RNASEL | |
| Rdv-Tp SCHEMBL24492746 | 0.75 | POLRMT (0.51) | P2RX1P2RX3P2RX2P2RX4RNASEL | |
| SCHEMBL25821559 | 0.74 | RNASEL (0.42) | P2RX1P2RX3P2RX2P2RX4RNASEL | |
| SCHEMBL25821565 | 0.74 | RNASEL (0.42) | P2RX1P2RX3P2RX2P2RX4RNASEL | |
| SCHEMBL25826041 | 0.74 | RNASEL (0.42) | P2RX1P2RX3P2RX2P2RX4RNASEL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250109157-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | GILEAD SCIENCES, INC. | 2025-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250109157-A1 | COMPOUNDS AND METHODS FOR TREATMENT OF VIRAL INFECTIONS | HAVCR2, GOT1, GOT2 | P2RX1 2064/4885P2RX3 2192/4885P2RX2 2259/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.